Clinical Trials Logo

Osteosarcoma clinical trials

View clinical trials related to Osteosarcoma.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06384404 Recruiting - Osteosarcoma Clinical Trials

Upfront Surgical Resection for Osteosarcoma

UFSR for OS
Start date: March 25, 2024
Phase:
Study type: Observational

The goal of this pilot study is to learn about patients with newly diagnosed osteosarcoma of an extremity, and whether surgically removing the tumor prior to the administration of any chemotherapy will improve functional outcomes. In order to learn about the patient's experience, the study team will administer questionnaires to the patient and surgeon at various timepoints to assess recovery and the function of the extremity.

NCT ID: NCT06324916 Recruiting - Osteosarcoma Clinical Trials

Donor Site Morbidity After Free Vascularized Fibular Graft

Start date: January 10, 2024
Phase:
Study type: Observational

This study was carried out at Assiut University to Asses the long-term donor site morbidity following free vascularized fibular transfer because there is a limited information regarding the long-term donor morbidity of this type of flap.

NCT ID: NCT06228326 Recruiting - Clinical trials for Metastatic Colorectal Cancer

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Start date: April 17, 2024
Phase: Phase 1
Study type: Interventional

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector that is designed to stimulate an anti-tumor immune response through the production of cytokines delivered to the airways of people with advanced solid tumor malignancies affecting the lungs via nebulization. This Phase 1, open-label, multicenter, dose escalation and expansion study is designed to evaluate the safety and tolerability of KB707 in adults with with advanced solid tumor malignancies affecting the lungs who have progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy. The study will include a dose escalation portion for single agent KB707 using a standard 3+3 design followed by an expansion portion to further evaluate single agent KB707 at a dose determined by preliminary data in the dose escalation phase. Subjects in both the dose escalation and dose expansion cohorts will receive KB707 via nebulization weekly for three weeks, then every three weeks for up to two years until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.

NCT ID: NCT06217224 Recruiting - Mucositis Oral Clinical Trials

Evaluation of Prophylactic Photobiomodulation Therapy in Patients With Osteosarcoma

PBMT/MTX
Start date: October 17, 2022
Phase: N/A
Study type: Interventional

This study aims to evaluate the photobiomodulation therapy (PBMT) for the prevention of oral mucositis in osteosarcoma patients submitted to high doses of methotrexate, through two different protocols. As a hypothesis, photobiomodulation for the prevention of oral mucositis after cycles of Cisplatin, Doxorubicin and Methotrexate is more effective than just the application of preventive low-power laser after Methotrexate alone.

NCT ID: NCT06171282 Recruiting - Sarcoma Clinical Trials

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors

Start date: July 12, 2023
Phase: Early Phase 1
Study type: Interventional

9 participants are expected to be enrolled for this open,Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced bone and soft tissue tumors.

NCT ID: NCT06156410 Recruiting - Osteosarcoma Clinical Trials

Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma

Start date: October 24, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory Ewing sarcoma and osteosarcoma.

NCT ID: NCT06129903 Recruiting - Sarcoma Clinical Trials

Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma

Start date: November 7, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the feasibility of early access to mental healthcare during sarcoma treatment as well as to assess the association between early access to psychiatric care and depression, anxiety, postoperative outcomes, and patient satisfaction in patients undergoing surgery for musculoskeletal sarcoma.

NCT ID: NCT06117878 Recruiting - Soft Tissue Sarcoma Clinical Trials

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

Start date: September 1, 2022
Phase: Early Phase 1
Study type: Interventional

This study will evaluate the safety and efficacy of NK510 in the treatment of Osteosarcoma and Soft Tissue Sarcoma.NK510 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

NCT ID: NCT06114225 Recruiting - Osteosarcoma Clinical Trials

Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial

PROMIS
Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate the efficacy and safety of pre-operative concurrent Stereotactic Body Radiotherapy (SBRT) and and programmed cell death protein-1 (PD-1) blockade immunotherapy followed by surgical metastasectomy for resectable metastatic osteosarcoma.

NCT ID: NCT06068075 Recruiting - Ewing Sarcoma Clinical Trials

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

Start date: May 8, 2018
Phase: N/A
Study type: Interventional

This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.